Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Prostate Cancer
Interventions: ARRx, Enzalutamide; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Contraception
Interventions: FemBloc; Device
Lead sponsor: Femasys Inc.; Industry
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: Chandler, Arizona • Phoenix, Arizona • Columbus, Georgia + 3 more

Conditions: Myeloid Leukemia, Philadelphia Positive
Interventions: Asciminib Pediatric formulation group, Asciminib Adult formulation group; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 8
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more

Conditions: Pyoderma Gangrenosum
Interventions: adalimumab; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: MIJ821, Placebo, Ketamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Hypertension
Interventions: Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more

Conditions: Tourette Syndrome
Interventions: Active Treatment, Sham Treatment; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Liver Fibroses, Cirrhosis
Interventions: Atorvastatin 20mg, Placebo; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Migraines
Interventions: divalproex sodium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Corneal Edema, Corneal Endothelial Dysfunction
Interventions: AURN001, Corneal Endothelial Cells, Y27632; Combination Product · Biological · Drug
Lead sponsor: Aurion Biotech; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: E. Coli Strain M17 Probiotic; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: recombinant human mannose-binding lectin; Biological
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Endometriosis
Interventions: Placebo, Telapristone acetate; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Tucson, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 7 more

Conditions: Low Back Pain
Interventions: Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo; Drug
Lead sponsor: MEDRx USA, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Carlsbad, California • Miami, Florida • New York, New York + 4 more

Conditions: Type 1 Diabetes
Interventions: 530G Insulin pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 12 more

Conditions: Cushing's Disease
Interventions: Lu AG13909; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • St Louis, Missouri

Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: PIT565; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Miami, Florida • Chicago, Illinois • Fairway, Kansas + 2 more

Conditions: Prader Willi Syndrome, Adrenal Insufficiency
Interventions: Low dose (1 mcg) ACTH stimulation test, Overnight metyrapone test; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 2 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Parkinson's Disease
Interventions: Accordion Pill™ Carbidopa/Levodopa; Drug
Lead sponsor: Intec Pharma Ltd.; Industry
Eligibility: 30 Years to 100 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more

Conditions: Dry Eye
Interventions: DE-101 ophthalmic suspension, DE-101 ophthalmic suspension vehicle; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 10
States / cities: Inglewood, California • Torrance, California • Bloomfield, Connecticut + 7 more

Conditions: Relapsed Breast Cancer, Neoplasms, Breast
Interventions: Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more

Search by objective public record fields.

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

FemBloc® Permanent Contraception - Confirmation Feasibility Trial

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Multi-site Transcranial Magnetic Stimulation Therapy of the Supplementary Motor Area in Children With Tourette Syndrome

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

Threshold Suspend in Pediatrics at Home

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer